Reasons for Geographic and Racial Differences in Stroke Cardiorenal GWAS

Request Access

Anthropometry (4)

BMI - Baseline body mass index, BMI (phv00525597.v1.p1)
BMI_s - Follow-up body mass index, BMI (phv00525614.v1.p1)
Waist_cm - Baseline waist circumference (phv00525598.v1.p1)
Waist_cm_s - Follow-up waist circumference (phv00525615.v1.p1)

Biomarkers (30)

ACR - Urine albumin to creatinine ratio (phv00525572.v1.p1)
ACR_s - Urine albumin to creatinine ratio at follow-up (phv00525583.v1.p1)
Albumin_urine - Urinary albumin (phv00525573.v1.p1)
Albumin_urine_s - Urinary albumin at follow-up (phv00525584.v1.p1)
Albuminuria - Urine albumin to creatinine ratio (ACR) >= 30 mg/g (phv00525580.v1.p1)
Bun - Blood urea nitrogen (phv00525574.v1.p1)
Creatinine_serum - Isotope Dilution Mass Spectroscopy (IDMS) calibrated serum creatinine (phv00525570.v1.p1)
Creatinine_serum_s - Isotope Dilution Mass Spectroscopy (IDMS) calibrated serum creatinine at follow-up (phv00525581.v1.p1)
Cysc - Cystatin c (phv00525571.v1.p1)
Cysc_s - Cystatin c at follow-up (phv00525582.v1.p1)
DBP - Diastolic blood pressure - average of two measures at baseline (phv00525526.v1.p1)
DBP_s - Diastolic blood pressure - average of two measures at follow-up (phv00525530.v1.p1)
EGFR_2009 - CKD-EPI estimated glomerular filtration rate with creatinine (2009) fit with race multiplier (phv00525577.v1.p1)
EGFR_CKDEPI_s - Estimated glomerular filtration rate from the CKD-Epi equation (Ref: Levey et al. Annals of Int Med 2009) at follow-up visit (phv00525585.v1.p1)
EGFR_cr2021 - CKD-EPI estimated glomerular filtration rate with creatinine only (2021) fit without race multiplier (phv00525576.v1.p1)
EGFR_crcysc2021 - CKD-EPI estimated glomerular filtration rate with creatinine and cystatin C (2021) fit without race multiplier (phv00525575.v1.p1)
Glucose - Serum glucose (phv00525600.v1.p1)
HDL - Baseline high density lipoprotein cholesterol (phv00525537.v1.p1)
HDL_s - Follow-up visit high density lipoprotein cholesterol (phv00525546.v1.p1)
Insulin - Serum insulin (phv00525601.v1.p1)
LDL - Baseline low density lipoprotein cholesterol (phv00525538.v1.p1)
LDL_s - Follow-up visit low density lipoprotein cholesterol (phv00525547.v1.p1)
Lipidemia - Dyslipidemia if TC >=240mg/dL OR LDL >=160 mg/dL OR HDL<=40 mg/dL OR on medicine at baseline (phv00525540.v1.p1)
Lipidemia_s - Dyslipidemia if TC >=240mg/dL OR LDL >=160 mg/dL OR HDL<=40 mg/dL OR on medicine at follow-up (phv00525549.v1.p1)
SBP - Systolic blood pressure - average of two measures at baselne (phv00525525.v1.p1)
SBP_S - Systolic blood pressure - average of two measures at follow-up (phv00525529.v1.p1)
TC - Baseline total cholesterol (phv00525536.v1.p1)
TC_s - Follow-up visit total cholesterol (phv00525545.v1.p1)
Trig - Baseline triglycerides (phv00525539.v1.p1)
Trig_s - Follow-up visit triglycerides (phv00525548.v1.p1)

Demographics (4)

Age - Age at baseline (phv00525587.v1.p1)
Age_s - Age at follow-up (phv00525609.v1.p1)
Sex - Gender (phv00525589.v1.p1)
SEX - Biological sex (phv00525517.v1.p1)

Disease Events (12)

CAD_Hx - History of heart disease (self-reported myocardial infarction, coronary artery bypass graft, bypass, angioplasty, or stenting OR evidence of myocardial infarction via electrocardiogram) (phv00525606.v1.p1)
CHD - Total coronary heart disease- first event of first definite/probable myocardial infarction OR definite/probable acute coronary heart disease death on/before December 31, 2018 (phv00525559.v1.p1)
CHDREV - Total coronary heart disease including revascularization- first event of first definite/probable myocardial infarction OR revascularization OR definite/probable acute coronary heart disease death on/before December 31, 2018 (phv00525560.v1.p1)
CKD - Prevalent chronic kidney disease (CKD) status; estimated glomerular filtration rate < 60 (phv00525579.v1.p1)
Dialysis_Hx - Self-reported dialysis (phv00525578.v1.p1)
DM - Diabetic if fasting glucose >=126 mg/dL; non-fasting glucose >= 200 mg/dL or pills or insulin at baseline (phv00525599.v1.p1)
DM_s - Diabetic if fasting glucose >=126 mg/dL; non-fasting glucose >= 200 mg/dL or pills or insulin at follow-up (phv00525616.v1.p1)
Hemorrhagic_Stroke - Incident hemorrhagic stroke on/before September 30, 2021 (phv00525553.v1.p1)
Ischemic_Stroke - Incident ischemic stroke on/before September 30, 2021 (phv00525552.v1.p1)
MI - First definite/probable myocardial infarction on/before December 31, 2018 (phv00525557.v1.p1)
MI_Hx - History of myocardial infarction (self-reported myocardial infarction OR evidence of myocardial infarction via electrocardiogram) (phv00525607.v1.p1)
Stroke_Hx - Participant reported previous stroke at baseline (phv00525605.v1.p1)

Medications (6)

AHT_current - Self-reported current use of anti-hypertensive medication at baseline (phv00525524.v1.p1)
AHT_current_s - Self-reported current use of anti-hypertensive medication at follow-up (phv00525534.v1.p1)
AHT_ever - Self-reported ever having used anti-hypertensive medication at baseline (phv00525523.v1.p1)
AHT_ever_s - Self-reported ever having used anti-hypertensive medication at follow-up (phv00525533.v1.p1)
LipidLoweringAgent - Self-reported if on lipid lowering agent (phv00525543.v1.p1)
Statin - Self-reported if on statin (phv00525541.v1.p1)

Race and Ethnicity (1)

Race - Race (phv00525588.v1.p1)

Socioeconomic (4)

Education - Highest education level described at baseline computer assisted telephone interview (phv00525591.v1.p1)
Income - Income category described at baseline computer assisted telephone interview (phv00525590.v1.p1)
Income_s - Income category at follow-up (phv00525610.v1.p1)
RelationshipStatus - Self-reported relationship status (phv00525594.v1.p1)

Substance Use (3)

Smoke - Self-reported smoking status at baseline (phv00525595.v1.p1)
Smoke_Current - Self-reported current smoking status at baseline (phv00525596.v1.p1)
Smoke_current_s - Self-reported current smoking status at follow-up (phv00525613.v1.p1)

Other (48)

Alc_NIAAA - Alcohol use per week described at baseline computer assisted telephone interview from the National Institute on Alcohol Abuse and Alcoholism (NIAAA) (phv00525593.v1.p1)
Alc_NIAAA_s - Alcohol use per week described at follow-up computer assisted telephone interview from the National Institute on Alcohol Abuse and Alcoholism (NIAAA) (phv00525612.v1.p1)
Alc_Use - Alcohol use described at baseline computer assisted telephone interview (phv00525592.v1.p1)
Alc_Use_s - Alcohol use described at follow-up computer assisted telephone interview (phv00525611.v1.p1)
All_Stroke_Days - Days to All_Stroke (phv00525563.v1.p1)
ANALYTE_TYPE - Analyte Type (phv00525619.v1.p1)
ANALYTE_TYPE - Analyte Type (phv00525624.v1.p1)
BODY_SITE - Body site where sample was collected (phv00525618.v1.p1)
BODY_SITE - Body site where sample was collected (phv00525623.v1.p1)
Calling_Algorithm - Software used to make calls (phv00525621.v1.p1)
Calling_Algorithm - Software used to make calls (phv00525626.v1.p1)
CHD_Days - Days to CHD (phv00525564.v1.p1)
CHDREV_Days - Days to CHDREV (phv00525565.v1.p1)
CONSENT - Consent group as determined by DAC (phv00525516.v1.p1)
DaysBetweenVisits - Number of days between baseline and follow-up visit (phv00525608.v1.p1)
Fasted - Did the participant fast prior to blood draw (phv00525602.v1.p1)
Genotyping_Platform - Genotyping platform used (phv00525620.v1.p1)
Genotyping_Platform - Genotyping platform used (phv00525625.v1.p1)
Hemorrhagic_Stroke_Days - Days to Hemorrhagic_Stroke (phv00525561.v1.p1)
HFevent - First heart failure hospitalization or death on/before December 31, 2018 (phv00525556.v1.p1)
HFevent_Days - Days to HFevent (phv00525566.v1.p1)
HFHosp - First heart failure hospitalization on/before December 31, 2018 (phv00525555.v1.p1)
HFHosp_Days - Days to HFHosp (phv00525567.v1.p1)
HTN_130 - Hypertensive new guideline: if SBP>=130 mmHg or DBP>=80 mmHg or self-reported current medication use to control blood pressure at baseline (phv00525528.v1.p1)
HTN_130_s - Hypertensive new guideline: if SBP>=130 mmHg or DBP>=80 mmHg or self-reported current medication use to control blood pressure at follow-up (phv00525532.v1.p1)
HTN_140 - Hypertensive if SBP>=140 mmHg or DBP>=90 mmHg or self-reported current medication use to control blood pressure at baseline (phv00525527.v1.p1)
HTN_140_s - Hypertensive if SBP>=140 mmHg or DBP>=90 mmHg or self-reported current medication use to control blood pressure at follow-up (phv00525531.v1.p1)
Incident_HF_indicator - Indicator for inclusion in incident heart failure analyses (phv00525554.v1.p1)
Ischemic_Stroke_Days - Days to Ischemic_Stroke (phv00525562.v1.p1)
LLA_Generic_Name - Generic name of lipid lowering agent (phv00525544.v1.p1)
MI_Days - Days to MI (phv00525568.v1.p1)
MI_Type - Indicator for myocardial infarction (MI variable) (phv00525558.v1.p1)
REGARDS_ID - Subject ID (phv00525586.v1.p1)
REGARDS_ID - Subject ID (phv00525550.v1.p1)
REGARDS_ID - Subject ID (phv00525569.v1.p1)
REGARDS_ID - Subject ID (phv00525535.v1.p1)
REGARDS_ID - Subject ID (phv00525522.v1.p1)
REGARDS_ID - Subject ID (phv00525515.v1.p1)
REGARDS_ID - Subject ID (phv00525520.v1.p1)
Region - Region from Geocoding (stroke belt; stroke belt buckle; non-stroke belt) (phv00525603.v1.p1)
Ruca_4class - 4 category rural-urban commuting areas (RUCA) 2000 classification (phv00525604.v1.p1)
SAMPLE_ID - Sample ID (phv00525617.v1.p1)
SAMPLE_ID - Sample ID (phv00525622.v1.p1)
SAMPLE_ID - Sample ID (phv00525521.v1.p1)
SOURCE_SUBJECT_ID - Subject ID used in the Source Repository (phv00525519.v1.p1)
Statin_Generic_Name - Generic name of statin (phv00525542.v1.p1)
Stroke - Incident stroke on/before September 30, 2021 (phv00525551.v1.p1)
SUBJECT_SOURCE - Source repository where subjects originate (phv00525518.v1.p1)